Relationship between the IL23R SNPs and Crohn’s Disease Susceptibility and Phenotype in the Polish and Bosnian Populations: A Case-Control Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Participants
2.2. DNA Extraction and Genotyping
2.3. Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Conflicts of Interest
References
- Baumgart, D.C.; Sandborn, W.J. Crohn’s disease. Lancet 2012, 380, 1590–1605. [Google Scholar] [CrossRef]
- De Souza, H.S.; Fiocchi, C. Immunopathogenesis of IBD: Current state of the art. Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 13–27. [Google Scholar] [CrossRef] [PubMed]
- Siakavellas, S.I.; Bamias, G. Role of the IL-23/IL-17 axis in Crohn’s disease. Discov. Med. 2012, 14, 253–262. [Google Scholar] [PubMed]
- Cătană, C.S.; Berindan-Neagoe, I.; Cozma, V.; Magdaş, C.; Tăbăran, F.; Dumitraşcu, D.L. Contribution of the IL-17/IL-23 axis to the pathogenesis of inflammatory bowel disease. World J. Gastroenterol. 2015, 21, 5823–5830. [Google Scholar] [CrossRef]
- Hue, S.; Ahern, P.; Buonocore, S.; Kullberg, M.C.; Cua, D.J.; McKenzie, B.S.; Powrie, F.; Maloy, K.J. Interleukin-23 drives innate and T cell-mediated intestinal inflammation. J. Exp. Med. 2006, 203, 2473–2483. [Google Scholar] [CrossRef] [PubMed]
- Elson, C.O.; Cong, Y.; Weaver, C.T.; Schoeb, T.R.; McClanahan, T.K.; Fick, R.B.; Kastelein, R.A. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007, 132, 2359–2370. [Google Scholar] [CrossRef]
- Wolk, K.; Witte, E.; Hoffmann, U.; Doecke, W.D.; Endesfelder, S.; Asadullah, K.; Sterry, W.; Volk, H.D.; Wittig, B.M.; Sabat, R. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: A potential systemic role of IL-22 in Crohn’s disease. J. Immunol. 2007, 178, 5973–5981. [Google Scholar] [CrossRef]
- Schmechel, S.; Konrad, A.; Diegelmann, J.; Glas, J.; Wetzke, M.; Paschos, E.; Lohse, P.; Göke, B.; Brand, S. Linking genetic susceptibility to Crohn’s disease with Th17 cell function: IL-22 serum levels are increased in Crohn’s disease and correlate with disease activity and IL23R genotype status. Inflamm. Bowel Dis. 2008, 14, 204–212. [Google Scholar] [CrossRef]
- Fujino, S.; Andoh, A.; Bamba, S.; Ogawa, A.; Hata, K.; Araki, Y.; Bamba, T.; Fujiyama, Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003, 52, 65–70. [Google Scholar] [CrossRef] [Green Version]
- Jiang, W.; Su, J.; Zhang, X.; Cheng, X.; Zhou, J.; Shi, R.; Zhang, H. Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease. Inflamm. Res. 2014, 63, 943–950. [Google Scholar] [CrossRef]
- Nielsen, O.H.; Kirman, I.; Rüdiger, N.; Hendel, J.; Vainer, B. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Scand. J. Gastroenterol. 2003, 38, 180–185. [Google Scholar] [CrossRef]
- Monteleone, G.; Monteleone, I.; Fina, D.; Vavassori, P.; Del Vecchio Blanco, G.; Caruso, R.; Tersigni, R.; Alessandroni, L.; Biancone, L.; Naccari, G.C.; et al. Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn’s disease. Gastroenterology 2005, 128, 687–694. [Google Scholar] [CrossRef] [PubMed]
- Annunziato, F.; Cosmi, L.; Santarlasci, V.; Maggi, L.; Liotta, F.; Mazzinghi, B.; Parente, E.; Filì, L.; Ferri, S.; Frosali, F.; et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 2007, 204, 1849–1861. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Parham, C.; Chirica, M.; Timans, J.; Vaisberg, E.; Travis, M.; Cheung, J.; Pflanz, S.; Zhang, R.; Singh, K.P.; Vega, F.; et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12R-beta-1 and a novel cytokine receptor subunit, IL-23R. J. Immun. 2002, 168, 5699–5708. [Google Scholar] [CrossRef] [PubMed]
- Duerr, R.H.; Taylor, K.D.; Brant, S.R.; Rioux, J.D.; Silverberg, M.S.; Daly, M.J.; Steinhart, A.H.; Abraham, C.; Regueiro, M.; Griffiths, A.; et al. A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene. Science 2006, 314, 1461–1463. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eken, A.; Singh, A.K.; Oukka, M. Interleukin 23 in Crohn’s disease. Inflamm. Bowel Dis. 2014, 20, 587–595. [Google Scholar] [CrossRef]
- Xu, W.D.; Xie, Q.B.; Zhao, Y.; Liua, Y. Association of Interleukin-23 receptor gene polymorphisms with susceptibility to Crohn’s disease: A meta-analysis. Sci. Rep. 2015, 5, 18584. [Google Scholar] [CrossRef] [Green Version]
- Rioux, J.D.; Xavier, R.J.; Taylor, K.D.; Silverberg, M.S.; Goyette, P.; Huett, A.; Green, T.; Kuballa, P.; Barmada, M.M.; Datta, L.W.; et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 2007, 39, 596–604. [Google Scholar] [CrossRef] [Green Version]
- Raelson, J.V.; Little, R.D.; Ruether, A.; Fournier, H.; Paquin, B.; Van Eerdewegh, P.; Bradley, W.E.; Croteau, P.; Nguyen-Huu, Q.; Segal, J.; et al. Genome-wide association study for Crohn’s disease in the Quebec Founder Population identifies multiple validated disease loci. Proc. Natl. Acad. Sci. USA 2007, 104, 14747–14752. [Google Scholar] [CrossRef]
- Zhang, L.; Lu, Y.; Ge, Y.; Shi, Y.; Wu, X.; Xu, Q.; Li, X.; Lu, L.; Zhang, F.; Yao, G. Interleukin-23R rs7517847 T/G Polymorphism Contributes to the Risk of Crohn’s Disease in Caucasians: A Meta-Analysis. J. Immunol. Res. 2015, 2015, 279849. [Google Scholar] [CrossRef]
- Li, X.; Song, P.; Timofeeva, M.; Meng, X.; Rudan, I.; Little, J.; Satsangi, J.; Campbell, H.; Theodoratou, E. Systematic meta-analyses and field synopsis of genetic and epigenetic studies in paediatric inflammatory bowel disease. Sci. Rep. 2016, 6, 34076. [Google Scholar] [CrossRef] [Green Version]
- Oliver, J.; Rueda, B.; López-Nevot, M.A.; Gómez-García, M.; Martín, J. Replication of an association between IL23R gene polymorphism with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2007, 5, 977–981. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.Y.; Zhang, H.J.; Zhang, Y.; Fu, Y.J.; He, J.; Zhu, L.P.; Wang, S.H.; Liu, L. Identification and expression analysis of alternatively spliced isoforms of human interleukin-23 receptor gene in normal lymphoid cells and selected tumor cells. Immunogenetics 2006, 57, 934–943. [Google Scholar] [CrossRef]
- Kan, S.H.; Mancini, G.; Gallagher, G. Identification and characterization of multiple splice forms of the human interleukin-23 receptor alpha chain in mitogen-activated leukocytes. Genes Immun. 2008, 9, 631–639. [Google Scholar] [CrossRef] [PubMed]
- Sáfrány, E.; Pazár, B.; Csöngei, V.; Járomi, L.; Polgár, N.; Sipeky, C.; Horváth, I.F.; Zeher, M.; Poór, G.; Melegh, B. Variants of the IL23R gene are associated with ankylosing spondylitis but not with Sjögren syndrome in Hungarian population samples. Scand. J. Immunol. 2009, 70, 68–74. [Google Scholar] [CrossRef]
- Jauregui-Amezaga, A.; Michael Somers, M.; Schepper, H.; Macken, E. Next generation of biologics for the treatment of Crohn’s disease: An evidence-based review on ustekinumab. Clin. Exp. Gastroenterol. 2017, 10, 293–301. [Google Scholar] [CrossRef] [PubMed]
- Sivanesan, D.; Beauchamp, C.; Quinou, C.; Lee, J.; Lesage, S.; Chemtob, S.; Rioux, J.D.; Michnick, S.W. IL23R (Interleukin 23 Receptor) Variants Protective against Inflammatory Bowel Diseases (IBD) Display Loss of Function due to Impaired Protein Stability and Intracellular Trafficking. J. Biol. Chem. 2016, 291, 8673–8685. [Google Scholar] [CrossRef]
- Van Assche, G.; Dignass, A.; Panes, J.; Beaugerie, L.; Karagiannis, J.; Allez, M.; Ochsenkühn, T.; Orchard, T.; Rogler, G.; Louis, E.; et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J. Crohns Colitis 2010, 4, 7–27. [Google Scholar] [CrossRef]
- Satsangi, J.; Silverberg, M.S.; Vermeire, S.; Colombel, J.F. The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 2006, 55, 749–753. [Google Scholar] [CrossRef]
- Behzadi, P.; Behzadi, E.; Ranjbar, R. The Incidence and Prevalence of Crohn’s Disease in Global Scale. SOJ Immunol. 2015, 3, 1–6. [Google Scholar] [CrossRef]
- Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet 2018, 390, 2769–2778. [Google Scholar] [CrossRef]
- Ferguson, L.R.; Han, D.Y.; Fraser, A.G.; Huebner, C.; Lam, W.J.; Morgan, A.R. IL23R and IL12B SNPs and Haplotypes Strongly Associate with Crohn’s Disease Risk in a New Zealand Population. Gastroenterol. Res. Pract. 2010, 2010, 539461. [Google Scholar] [CrossRef]
- Doecke, J.D.; Simms, L.A.; Zhao, Z.Z.; Roberts, R.L.; Fowler, E.V.; Croft, A.; Lin, A.; Huang, N.; Whiteman, D.C.; Florin, T.H.; et al. Smoking behaviour modifies IL23r-associated disease risk in patients with Crohn’s disease. J. Gastroenterol. Hepatol. 2015, 30, 299–307. [Google Scholar] [CrossRef]
- Glas, J.; Seiderer, J.; Wetzke, M.; Konrad, A.; Török, H.P.; Schmechel, S.; Tonenchi, L.; Grassl, C.; Dambacher, J.; Pfennig, S.; et al. rs1004819 is the main disease-associated IL23R variant in German Crohn’s disease patients: Combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS ONE 2007, 2, e819. [Google Scholar] [CrossRef]
- Cummings, J.R.; Ahmad, T.; Geremia, A.; Beckly, J.; Cooney, R.; Hancock, L.; Pathan, S.; Guo, C.; Cardon, L.R.; Jewell, D.P. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflamm. Bowel Dis. 2007, 13, 1063–1068. [Google Scholar] [CrossRef] [PubMed]
- Tremelling, M.; Cummings, F.; Fisher, S.A.; Mansfield, J.; Gwilliam, R.; Keniry, A.; Nimmo, E.R.; Drummond, H.; Onnie, C.M.; Prescott, N.J.; et al. IL-23R Variation Determines Susceptibility But Not Disease Phenotype in Inflammatory Bowel Disease. Gastroenterology 2007, 132, 1657–1664. [Google Scholar] [CrossRef] [PubMed]
- Lappalainen, M.; Halme, L.; Turunen, U.; Saavalainen, P.; Einarsdottir, E.; Färkkilä, M.; Kontula, K.; Paavola-Sakki, P. Association of IL23R, TNFRSF1A, and HLA-DRB1*0103 allele variants with inflammatory bowel disease phenotypes in the Finnish population. Inflamm. Bowel Dis. 2008, 14, 1118–1124. [Google Scholar] [CrossRef] [PubMed]
- Einarsdottir, E.; Koskinen, L.L.; Dukes, E.; Kainu, K.; Suomela, S.; Lappalainen, M.; Ziberna, F.; Korponay-Szabo, I.R.; Kurppa, K.; Kaukinen, K.; et al. IL23R in the Swedish, Finnish, Hungarian and Italian populations: Association with IBD and psoriasis, and linkage to celiac disease. BMC Med. Genet. 2009, 10, 8. [Google Scholar] [CrossRef]
- Jakubowska-Burek, L.; Kaczmarek, E.; Hoppe-Golebiewska, J.; Kaczmarek-Rys, M.; Hryhorowicz, S.; Kucharski, M.A.; Slomski, R.; Linke, K.; Dobrowolska-Zachwieja, A. Genotyping of CARD15/NOD2, ATG16L1 and IL23R Genes in Polish Crohn’s Disease (CD) Patients—Are They Related to the Localization of the Disease and Extra-Intestinal Symptoms? In Crohn’s Disease; Karoui, S., Ed.; InTech: Rijeka, Croatia, 2012; pp. 39–58. ISBN 978-953-307-811-3. [Google Scholar]
- Newman, W.G.; Zhang, Q.; Liu, X.; Amos, C.I.; Siminovitch, K.A. Genetic variants in IL-23R and ATG16L1 independently predispose to increased susceptibility to Crohn’s disease in a Canadian population. J. Clin. Gastroenterol. 2009, 43, 444–447. [Google Scholar] [CrossRef] [PubMed]
- Mitrovič, M.; Potočnik, U. High Resolution Melting Curve Analysis for High-Throughput SNP Genotyping in IL23R Gene and Association of IL23R with Slovenian Inflammatory Bowel Diseases Patients. Acta Chim. Slov. 2010, 57, 498–505. [Google Scholar] [PubMed]
- Latiano, A.; Palmieri, O.; Valvano, M.R.; D’Incà, R.; Cucchiara, S.; Riegler, G.; Staiano, A.M.; Ardizzone, S.; Accomando, S.; de Angelis, G.L.; et al. Replication of interleukin 23 receptor and autophagy-related 16-like 1 association in adult- and pediatric-onset inflammatory bowel disease in Italy. World J. Gastroenterol. 2008, 14, 4643–4651. [Google Scholar] [CrossRef] [Green Version]
- Márquez, A.; Mendoza, J.L.; Taxonera, C.; Díaz-Rubio, M.; De La Concha, E.G.; Urcelay, E.; Martínez, A. IL23R and IL12B polymorphisms in Spanish IBD patients: No evidence of interaction. Inflamm. Bowel Dis. 2008, 14, 1192–1196. [Google Scholar] [CrossRef]
- Lauriola, M.; Ugolini, G.; Rivetti, S.; Nanì, S.; Rosati, G.; Zanotti, S.; Montroni, I.; Manaresi, A.; Zattoni, D.; Belluzzi, A.; et al. IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn’s disease and correlation with sub-phenotypes. Int. J. Mol. Med. 2011, 27, 469–477. [Google Scholar] [CrossRef]
- Palmieri, O.; Bossa, F.; Valvano, M.R.; Corritore, G.; Latiano, T.; Martino, G.; D’Incà, R.; Cucchiara, S.; Pastore, M.; D’Altilia, M.; et al. Crohn’s Disease Localization Displays Different Predisposing Genetic Variants. PLoS ONE 2017, 12, e0168821. [Google Scholar] [CrossRef] [PubMed]
- Baptista, M.L.; Amarante, H.; Picheth, G.; Sdepanian, V.L.; Peterson, N.; Babasukuma, U.; Lima, H.C.; Kugathasan, S. CARD15 and IL23R influences Crohn’s disease susceptibility but not disease phenotype in a Brazilian population. Inflamm. Bowel Dis. 2008, 14, 674–679. [Google Scholar] [CrossRef] [PubMed]
- Yamazaki, K.; Onouchi, Y.; Takazoe, M.; Kubo, M.; Nakamura, Y.; Hata, A. Association analysis of genetic variants in IL23R, ATG16L1 and 5p13.1 loci with Crohn’s disease in Japanese patients. J. Hum. Genet. 2007, 52, 575–583. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chua, K.H.; Hilmi, I.; Lian, L.H.; Patmanathan, S.N.; Hoe, S.Z.; Lee, W.S.; Goh, K.L. Association between inflammatory bowel disease gene 5 (IBD5) and interleukin-23 receptor (IL23R) genetic polymorphisms in Malaysian patients with Crohn’s disease. J. Dig. Dis. 2012, 13, 459–465. [Google Scholar] [CrossRef] [PubMed]
Total, n = 294 | Poland, n = 234 | Bosnia and Herzegovina, n = 60 | |||
---|---|---|---|---|---|
CD, n = 117 | CD with Phenotypic Data, n = 99 | Controls, n = 117 | CD with Phenotypic Data, n = 30 | Controls, n = 30 | |
Sex | |||||
Males, n (%) | 59 (50.43) | 51 (51.52) | 59 (50.43) | 15 (50.00) | 14 (46.67) |
Females, n (%) | 58 (49.57) | 48 (48.48) | 58 (49.57) | 15 (50.00) | 16 (53.33) |
Age (years) | |||||
Mean ± SD | 35.15 ± 12.65 | 34.84 ± 12.18 | 35.62 ± 12.90 | 44.07 ± 14.53 | 61.30 ± 15.21 |
Min–Max | 18–68 | 18–66 | 18–68 | 18–80 | 25–83 |
Categories according to montreal classification (2005) | |||||
Age at diagnosis, n (%) | |||||
A1 (≤16 y) | – | 9 (9.09) | – | 1 (3.33) | – |
A2 (17–40 y) | – | 74 (74.75) | – | 7 (23.33) | – |
A3 (>40 y) | – | 16 (16.16) | – | 22 (73.34) | – |
Location, n (%) | |||||
L1 (terminal ileum) | – | 3 (3.03) | – | 12 (40.00) | – |
L2 (colon) | – | 35 (35.35) | – | 5 (16.67) | – |
L3 (ileocolon) | – | 61 (61.62) | – | 13 (43.33) | – |
L4 + (upper gastrointestinal tract +) | – | 6 (6.06) | – | – | – |
L4 − (upper gastrointestinal tract −) | – | 93 (93.94) | – | – | – |
Behaviour, n (%) | |||||
B1 (non-stricturing non-penetrating) | – | 54 (54.55) | – | 15 (50.00) | – |
B2 (stricturing) | – | 23 (23.23) | – | 8 (26.67) | – |
B3 (penetrating) | – | 22 (22.22) | – | 6 (20.00) | – |
B2 + B3 (structuring and penetrating) | – | – | – | 1 (3.33) | – |
p + (perianal disease +) | – | 14 (14.14) | – | 4 (13.33) | – |
p − (perianal disease −) | – | 85 (85.86) | – | 26 (86.67) | – |
IL23R Polymorphism | Poland, n = 234 | Bosnia and Herzegovina, n = 60 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
CD, n = 117 | Controls, n = 117 | χ2 (df) | p | OR (95% CI) | CD, n = 30 | Controls, n = 30 | χ2 (df) | p | OR (95% CI) | |
rs1004819 G > A | ||||||||||
Genotype, n (%) | ||||||||||
G/G | 44 (37.6) | 66 (56.4) | 9.35 (2) | 0.0093 * | – | 17 (56.7) | 16 (53.4) | 0.53 (2) | 0.7671* | – |
G/A | 56 (47.9) | 43 (36.8) | 11 (36.7) | 13 (43.3) | ||||||
A/A | 17 (14.5) | 8 (6.8) | 2 (6.6) | 1 (3.3) | ||||||
Genetic model | ||||||||||
Co-dominant | ||||||||||
G/G | 44 (37.6) | 66 (56.4) | – | – | 1.00 | 17 (56.7) | 16 (53.4) | – | – | 1.00 |
A/A | 17 (14.5) | 8 (6.8) | – | 0.0142 | 3.19 (1.27–8.02) | 2 (6.6) | 1 (3.3) | – | 1.0000 | 1.88 (0.16–22.85) |
G/G | 44 (37.6) | 66 (56.4) | – | – | 1.00 | 17 (56.7) | 16 (53.4) | – | – | 1.00 |
G/A | 56 (47.9) | 43(36.8) | – | 0.0188 | 1.95 (1.13–3.39) | 11 (36.7) | 13 (43.3) | – | 0.7901 | 0.80 (0.28–2.29) |
Dominant | ||||||||||
G/G | 44 (37.6) | 66 (56.4) | – | – | 1.00 | 17 (56.7) | 16 (53.4) | – | – | 1.00 |
A/A + G/A | 73 (62.4) | 51 (43.6) | – | 0.0058 | 2.15 (1.27–3.62) | 13 (43.3) | 14 (46.6) | – | 1.0000 | 0.87 (0.32–2.42) |
Recessive | ||||||||||
G/A + G/G | 100 (85.5) | 109 (93.2) | – | – | 1.00 | 28 (93.4) | 29 (96.7) | – | – | 1.00 |
A/A | 17 (14.5) | 8 (6.8) | – | 0.0889 | 2.32 (0.96–5.60) | 2 (6.6) | 1 (3.3) | – | 1.0000 | 2.07 (0.18–24.16) |
Allele n (%) | ||||||||||
G | 144 (61.5) | 175 (74.8) | – | – | 1.00 | 45 (75.0) | 45 (75.0) | – | – | 1.00 |
A | 90 (38.5) | 59 (25.2) | – | 0.0028 | 1.85 (1.25–2.75) | 15 (25.0) | 15 (25.0) | – | 1.0000 | 1.00 (0.44–2.29) |
rs7517847 T > G | ||||||||||
Genotype, n (%) | ||||||||||
T/T | 55 (47.0) | 38 (32.5) | 8.71 (2) | 0.0129 * | – | 10 (33.3) | 7 (23.3) | – | 0.1614 * | – |
T/G | 53 (45.3) | 57 (48.7) | 13 (43.4) | 20 (66.7) | 3.61 (2) | |||||
G/G | 9 (7.7) | 22 (18.8) | 7 (23.3) | 3 (10.0) | – | |||||
Genetic model | ||||||||||
Co-dominant | ||||||||||
T/T | 55 (47.0) | 38 (32.5) | – | – | 1.00 | 10 (33.3) | 7 (23.3) | – | – | 1.00 |
G/G | 9 (7.7) | 22 (18.8) | – | 0.0064 | 0.28 (0.12–0.68) | 7 (23.3) | 3 (10.0) | – | 0.6919 | 1.63 (0.31–8.61) |
T/T | 55 (47.0) | 38 (32.5) | – | – | 1.00 | 10 (33.3) | 7 (23.3) | – | – | 1.00 |
T/G | 53 (45.3) | 57 (48.7) | – | 0.1237 | 0.64 (0.37–1.12) | 13 (43.4) | 20 (66.7) | – | 0.2387 | 0.46 (0.14–1.50) |
Dominant | ||||||||||
T/T | 55 (47.0) | 38 (32.5) | – | – | 1.00 | 10 (33.3) | 7 (23.3) | – | – | 1.00 |
G/G + T/G | 62 (53.0) | 79 (67.5) | – | 0.0323 | 0.54 (0.32–0.92) | 20 (66.7) | 23 (76.7) | – | 0.5675 | 0.61 (0.20–1.90) |
Recessive | ||||||||||
T/G + T/T | 108 (92.3) | 95 (81.2) | – | – | 1.00 | 23 (76.7) | 27 (90.0) | – | – | 1.00 |
G/G | 9 (7.7) | 22 (18.8) | – | 0.0195 | 0.36 (0.16–0.82) | 7 (23.3) | 3 (10.0) | – | 0.2990 | 2.74 (0.63–11.83) |
Allele, n (%) | ||||||||||
T | 163 (69.7) | 133 (56.8) | – | – | 1.00 | 33 (55.0) | 34 (56.7) | – | – | 1.00 |
G | 71 (30.3) | 101 (43.2) | – | 0.0054 | 0.57 (0.39–0.84) | 27 (45.0) | 26 (43.3) | – | 1.0000 | 1.07 (0.52–2.20) |
Genotypes Co-Carriage | Poland, n = 234 | |||||
CD, n = 117 | Controls, n = 117 | p(1) | OR (95% CI) | p(2) | χ2 (df) | |
Homo- and heterozygous risk genotypes, n (%) | ||||||
0 | 31 (26.5) | 55 (47.0) | – | 1.00 | 0.0041 | 10.98 (2) |
1 | 44 (37.6) | 35 (29.9) | 0.0128 | 2.23 (1.19–4.17) | ||
2 | 42 (35.9) | 27 (23.1) | 0.0034 | 2.76 (1.44–5.31) | ||
Homozygous risk genotypes, n (%) | ||||||
0 | 62 (53.0) | 79 (67.6) | – | 1.00 | 0.0444 | 6.23 (2) |
1 | 38 (32.5) | 30 (25.6) | 0.1392 | 1.61 (0.90–2.89) | ||
2 | 17 (14.5) | 8 (6.8) | 0.0309 | 2.71 (1.10–6.69) | ||
Genotypes Co-Carriage | Bosnia and Herzegovina, n = 60 | |||||
CD, n = 30 | Controls, n = 30 | p(1) | OR (95% CI) | p(2) | χ2 (df) | |
Homo- and heterozygous risk genotypes, n (%) | ||||||
0 | 15 (50.0) | 13 (43.3) | – | 1.00 | 0.1943 | 3.28 (2) |
1 | 7 (23.3) | 13 (43.3) | 0.2489 | 0.47 (0.14–1.52) | ||
2 | 8 (26.7) | 4 (13.4) | 0.5048 | 1.73 (0.42–7.11) | ||
Homozygous risk genotypes, n (%) | ||||||
0 | 20 (66.7) | 23 (65.0) | – | 1.00 | 0.6609 | 0.83 (2) |
1 | 8 (26.7) | 6 (30.0) | 0.5497 | 1.53 (0.45–5.18) | ||
2 | 2 (6.6) | 1 (5.0) | 0.6000 | 2.30 (0.19–27.32) |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Borecki, K.; Zawada, I.; Salkić, N.N.; Karakiewicz, B.; Adler, G. Relationship between the IL23R SNPs and Crohn’s Disease Susceptibility and Phenotype in the Polish and Bosnian Populations: A Case-Control Study. Int. J. Environ. Res. Public Health 2019, 16, 1551. https://doi.org/10.3390/ijerph16091551
Borecki K, Zawada I, Salkić NN, Karakiewicz B, Adler G. Relationship between the IL23R SNPs and Crohn’s Disease Susceptibility and Phenotype in the Polish and Bosnian Populations: A Case-Control Study. International Journal of Environmental Research and Public Health. 2019; 16(9):1551. https://doi.org/10.3390/ijerph16091551
Chicago/Turabian StyleBorecki, Krzysztof, Iwona Zawada, Nermin Nusret Salkić, Beata Karakiewicz, and Grażyna Adler. 2019. "Relationship between the IL23R SNPs and Crohn’s Disease Susceptibility and Phenotype in the Polish and Bosnian Populations: A Case-Control Study" International Journal of Environmental Research and Public Health 16, no. 9: 1551. https://doi.org/10.3390/ijerph16091551